{"transactions":[{"id":916257,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-06T18:08:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":336300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":336300,"derivative":{"exercise_price":3.61,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":336300},"source":{"system":"sec-edgar","filing":"0002045027-26-000004","document":"form4-02062026_110205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000004/form4-02062026_110205.xml","form_type":"4"}},{"id":916256,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2026-02-06T18:08:08.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":96100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":96100,"derivative":{"underlying":"Common Stock","underlying_shares":96100},"source":{"system":"sec-edgar","filing":"0002045027-26-000004","document":"form4-02062026_110205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000004/form4-02062026_110205.xml","form_type":"4"}},{"id":918004,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2026-02-05T16:44:00.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":18675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":56025,"derivative":{"underlying":"Common Stock","underlying_shares":18675},"source":{"system":"sec-edgar","filing":"0002045027-26-000002","document":"form4-02052026_090256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000002/form4-02052026_090256.xml","form_type":"4"}},{"id":918003,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2026-02-05T16:44:00.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":18675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":45425,"source":{"system":"sec-edgar","filing":"0002045027-26-000002","document":"form4-02052026_090256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502726000002/form4-02052026_090256.xml","form_type":"4"}},{"id":980513,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2025-12-04T16:50:45.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":false,"shares":26750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."}],"balance_after":80250,"derivative":{"underlying":"Common Stock","underlying_shares":26750},"source":{"system":"sec-edgar","filing":"0002045027-25-000003","document":"form4-12042025_091242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502725000003/form4-12042025_091242.xml","form_type":"4"}},{"id":980512,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-12-04T16:50:45.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":true,"shares":26750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":26750,"source":{"system":"sec-edgar","filing":"0002045027-25-000003","document":"form4-12042025_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000204502725000003/form4-12042025_091242.xml","form_type":"4"}},{"id":1285379,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-04T16:15:17.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":261600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":261600,"derivative":{"exercise_price":2.4,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":261600},"source":{"system":"sec-edgar","filing":"0001415889-25-002942","document":"form4-02042025_040211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000141588925002942/form4-02042025_040211.xml","form_type":"4"}},{"id":1285378,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2025-02-04T16:15:17.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":74700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date."}],"balance_after":74700,"derivative":{"underlying":"Common Stock","underlying_shares":74700},"source":{"system":"sec-edgar","filing":"0001415889-25-002942","document":"form4-02042025_040211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000141588925002942/form4-02042025_040211.xml","form_type":"4"}},{"id":1345536,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Restricted Stock Units","published_at":"2024-12-03T17:42:38.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":107000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the \"Plan\") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Four year vesting with 25% of the shares subject to the restricted stock units vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service through each such date."}],"balance_after":107000,"derivative":{"expiration_date":"2034-12-01","underlying":"Common Stock","underlying_shares":107000},"source":{"system":"sec-edgar","filing":"0001415889-24-028178","document":"form4-12032024_101234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000141588924028178/form4-12032024_101234.xml","form_type":"4"}},{"id":1345535,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":67432,"kind":"person","name":"Davis Hugh M.","position":1,"cik":"0002045027","reported_name":"Davis Hugh M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-03T17:42:38.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the \"Plan\") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service (as defined in the Plan) through each such date."}],"balance_after":375000,"derivative":{"exercise_price":3.96,"expiration_date":"2034-12-01","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001415889-24-028178","document":"form4-12032024_101234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045027/000141588924028178/form4-12032024_101234.xml","form_type":"4"}}]}